Works Cited
- Back to Course Home
- Participation Instructions
- Review the course material online or in print.
- Complete the course evaluation.
- Review your Transcript to view and print your Certificate of Completion. Your date of completion will be the date (Pacific Time) the course was electronically submitted for credit, with no exceptions. Partial credit is not available.
1. English JF, Cundiff MY, Malone JD, et al.Bioterrorism Readiness Plan: A Template for Healthcare Facilities. Washington, DC: Association for Professionals in Infection Control and Epidemiology; 1999.
2. Ready.gov. Biohazard Exposure. Available at https://www.ready.gov/biohazard. Last accessed August 26, 2026.
3. Placer County Health and Human Services and Placer/Nevada County Medical Society.Zebra Primer on Bioterrorism. Auburn, CA: Placer County Health and Human Services; 2001.
4. Crutcher M. Response to biological terrorism. Paper presented at: Epidemiologists and Professionals in Infection Control (EPIC) Meeting; May 2000, Oklahoma City, OK.
5. Federal Bureau of Investigation. Amerithrax or Anthrax Investigation. Available at https://archives.fbi.gov/archives/about-us/history/famous-cases/anthrax-amerithrax. Last accessed August 26, 2026.
6. Office of the Assistant Secretary of Defense. DoD News Briefing. Proliferation: Threat and Response Briefing. Available at https://irp.fas.org/threat/prolif97/t11251997_t1125ptr.html. Last accessed August 26, 2026.
7. Merck Manual. CDC High-Priority Biological Agents and Toxins. Available at https://www.merckmanuals.com/home/multimedia/table/cdc-high-priority-biological-agents-and-toxins. Last accessed August 26, 2026.
8. Audi J, Belson M, Patel M, Schier J, Osterloh J. Ricin poisoning: a comprehensive review.JAMA. 2005;294(18):2342-2351.
9. Dembek ZF, Alves DA, Cieslak TJ, et al. (eds).USAMRIID's Medical Management of Biological Casualties Handbook. 7th ed. Fort Detrick, MD: U.S. Army Medical Research; 2011.
10. Wein LM, Liu Y. Analyzing a bioterror attack on the food supply: the case of botulinum toxin in milk.Proc Natl Acad Sci USA. 2005;102(28):9984-9989.
12. Weber DJ, Sickbert-Bennett E, Gergen MF, Rutala WA. Efficacy of selected hand hygiene agents used to remove Bacillus atrophaeus (a surrogate of Bacillus anthracis) from contaminated hands.JAMA. 2003;289(10):1274-1277.
13. Centers for Disease Control and Prevention. Anthrax. Bioterrorism and Anthrax: The Threat. Available at https://www.cdc.gov/anthrax/bioterrorism/. Last accessed August 26, 2026.
14. Katzman K. Iraq: Weapons Programs, U. N. Requirements, and U.S. Policy. Available at https://www.everycrsreport.com/reports/IB92117.html. Last accessed August 26, 2026.
15. Inglesby TV, O'Toole T, Henderson DA, et al.; Working Group on Civilian Biodefense. Anthrax as a biological weapon, 2002: updated recommendations for management.JAMA. 2002;287(17):2236-2252.
16. Centers for Disease Control and Prevention. About Anthrax. Available at https://www.cdc.gov/anthrax/about/. Last accessed August 26, 2026.
17. Bower WA, Schiffer J, Atmar RL, et al. Use of anthrax vaccine in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2019.MMWR. 2019;68(4):1-14.
18. Centers for Disease Control and Prevention. Travelers' Health. CDC Yellow Book. Table of ContentsCDC Yellow Book 2026: Section 4: Travel-Related Infections and Diseases - Bacterial. Available at https://www.cdc.gov/yellow-book/hcp/contents/index.html. Last accessed August 26, 2026.
19. Doganay M, Dinc G, Kutmanova A, Baillie L. Human anthrax: update of the diagnosis and treatment.Diagnostics (Basel). 2023;13(6):1056.
20. Johnson S. Response to bioterrorism: the role of laboratories. Paper presented at: Epidemiologists and Professionals in Infection Control (EPIC) Meeting; August 17, 2000; Oklahoma City, OK.
21. Stern EJ, Uhde KB, Shadomy SV, Messonnier N. Conference report on public health and clinical guidelines for anthrax.Emerg Infect Dis. 2008;14(4):e1.
22. Centers for Disease Control and Prevention. Anthrax. Laboratory Information for Anthrax Testing. Available at https://www.cdc.gov/anthrax/hcp/laboratories/index.html. Last accessed August 26, 2026.
23. Bower WA, Yu Y, Person MK, et al. CDC guidelines for the prevention and treatment of anthrax, 2023.MMWR. 2023;72(6):1-47.
24. Shifman O, Aminov T, Aftalion M, et al. Evaluation of the European Committee on Antimicrobial Susceptibility Testing guidelines for rapid antimicrobial susceptibility testing of Bacillus anthracis-, Yersinia pestis- and Francisella tularensis-positive blood cultures.Microorganisms. 2021;9(5):1055.
25. Martin GJ, Friedlander AM, Bacillus anthracis. In: Bennett JE, Dolin R, Blaser MJ (eds).Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 9th ed. Elsevier; Amsterdam, The Netherlands: 2020. pp. 2550–2569.
26. Hendricks KA, Wright ME, Shadomy SV, et al. Centers for Disease Control and Prevention expert panel meetings on prevention and treatment of anthrax in adults.Emerg Infect Dis. 2014;20(2):e130687.
27. Centers for Disease Control and Prevention. Clinical framework and medical countermeasure use during an anthrax mass-casualty incident: recommendations and reports.MMWR. 2015;64(RR4):1-28.
28. Wolfe DN, Espeland EM, Gao Y, et al. Evaluation of BioThrax and AV7909 anthrax vaccines in adults 66 years of age or older.Vaccine. 2020;38:7970-7976.
29. Jang KH, Nam S-J, Locke JB, et al. Anthracimycin, a potent anthrax antibiotic from a marine-derived actinomycete.Angew Chem Int Ed Engl. 2013;52(30):7822-7824.
30. Tian P, Ye W, Zhang X, Tong Y, Qian PY, Tong R. Ten-step asymmetric total syntheses of potent antibiotics anthracimycin and anthracimycin B.Chem Sci. 2022;13(43):12776-12781.
31. Jackson MA, Schutze GE; Committee on Infectious Diseases. The use of systemic and topical fluoroquinolones.Pediatrics. 2016;138:e20162706.
32. U.S. Food and Drug Administration. FDA Approves Treatment for Inhalation Anthrax. Available at https://wayback.archive-it.org/7993/20170405005211/https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm439752.htm. Last accessed August 26, 2026.
33. Advisory Committee on Immunization Practices. Notice to readers: use of anthrax vaccine in the response to terrorism: supplemental recommendations of the Advisory Committee on Immunization Practices.MMWR. 2002;51(45):1024-1026.
34. Centers for Disease Control and Prevention. Considerations for Anthrax Vaccine Adsorbed (AVA) Post-Exposure Prioritization Final. Available at https://www.cdc.gov/anthrax/pdf/ava-post-event-prioritization-guidance.pdf. Last accessed August 26, 2026.
35. Inglesby TV, Dennis DT, Henderson DA, et al. Plague as a biological weapon: medical and public health management.JAMA. 2000;283(17):2281-2290.
36. Centers for Disease Control and Prevention. About Plague. Available at https://www.cdc.gov/plague/about/index.html. Last accessed August 26, 2026.
38. Heymann DL (ed).Control of Communicable Disease Manual. 20th ed. Washington, DC: American Public Health Association; 2014.
39. Centers for Disease Control and Prevention. Plague: Clinical Testing and Diagnosis for Plague. Available at https://www.cdc.gov/plague/hcp/clinical-care/. Last accessed August 26, 2026.
40. Sha J, Endsley JJ, Kirtley ML, et al. Characterization of an F1 deletion mutant of Yersinia pestis CO92, pathogenic role of F1 antigen in bubonic and pneumonic plague, and evaluation of sensitivity and specificity of F1 antigen capture-based dipsticks.J Clin Microbiol. 2011;49(5):1708-1715.
41. Friedlander AM, Welkos SL, Worsham PL, et al. Relationship between virulence and immunity as revealed in recent studies of the F1 capsule of Yersinia pestis.Clin Infect Dis. 1995;21(Suppl 2):S178-S181.
42. Nelson CA, Meaney-Delman D, Fleck-Derderian S, et al. Antimicrobial treatment and prophylaxis of plague: recommendations for naturally acquired infections and bioterrorism response.MMWR. 2021;70(3):1-27.
43. Centers for Disease Control and Prevention. Plague: Clinical Care of Plague. Available at https://www.cdc.gov/plague/hcp/clinical-care/index.html. Last accessed August 26, 2026.
44. Boulanger LL, Ettestad P, Fogarty JD, et al. Gentamicin and tetracyclines for the treatment of human plague: review of 75 cases in New Mexico, 1985–1999.Clin Infect Dis. 2004;38:663-669.
45. Centers for Disease Control and Prevention. Guidance for Responding to a Plague Bioterrorism Event. Available at https://www.cdc.gov/plague/hcp/emergency-guidance/. Last accessed August 26, 2026.
46. Jefferson T, Demicheli V, Pratt M. Vaccines for preventing plague.Cochrane Database Syst Rev. 2000(2):CD000976.
47. Price JL, Manetz TS, Shearer JD, House RV. Preclinical safety assessment of a recombinant plague vaccine (rF1V).Int J Toxicol. 2013;32(5):327-335.
48. Biryukov S, Dankmeyer JL, Shamsuddin Z, et al. Impact of toll-like receptor-specific agonists on the host immune response to the Yersinia pestis plague rF1V vaccine.Front Immunol. 2021;12:726416.
49. Global Biodefense. FDA Grants Orphan Drug Designation for Plague Vaccine. Available at https://globalbiodefense.com/2017/03/10/fda-grants-orphan-drug-designation-plague-vaccine/. Last accessed August 26, 2026.
50. Dennis DT, Inglesby TV, Henderson DA, et al. Tularemia as a biological weapon: medical and public health management.JAMA. 2001;285(21):2763-2773.
51. Centers for Disease Control and Prevention. About Tularemia. Available at https://www.cdc.gov/tularemia/about/index.html. Last accessed August 26, 2026.
52. Cleveland KO. Tularemia. Available at https://emedicine.medscape.com/article/230923-overview. Last accessed August 26, 2026.
53. World Health Organization.Health Aspects of Chemical and Biological Weapons: Report of a WHO Group of Consultants. Geneva: World Health Organization; 1970.
54. Centers for Disease Control and Prevention. Clinical Signs and Symptms of Tularemia. Available at https://www.cdc.gov/tularemia/hcp/clinical-signs/index.html. Last accessed August 26, 2026.
55. Penn RL. Francisella tularensis (tularemia). In: Bennet JE, Dolin R, Blaser MJ (eds).Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 8th ed. New York, NY: Saunders; 2014: 2060-2068.
56. County of Los Angeles Department of Public Health and the Emergency Medical Services Agency of the Los Angeles County Department of Health Services.Terrorism Agent Information and Treatment Guidelines for Clinicians and Hospitals. Los Angeles, CA: County of Los Angeles Public Health; 2012.
57. Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America.Cin Infect Dis. 2014;59(2):e10-e52.
58. LexiDrug. Available at https://online.lexi.com. Last accessed August 26, 2026.
59. Hofinger DM, Cardona L, Mertz GJ, Davis LE. Tularemic meningitis in the United States.Arch Neurol. 2009;66(4):523-527.
60. Lamps LW, Havens JM, Sjostedt A, Page DL, Scott MA. Histologic and molecular diagnosis of tularemia: a potential bioterrorism agent endemic to North America.Mod Pathol. 2004;17(5):489-495.
61. Centers for Disease Control and Prevention. Tularemia. Reducing Risk. Available at https://www.cdc.gov/tularemia/hcp/clinical-care/infection-control-and-environmental-decontamination.html. Last accessed August 26, 2026.
62. French GR, Plotkin SA. Miscellaneous limited-use vaccines. In: Plotkin S, Orenstein W, Offit PA (eds).Vaccines. 6th ed. Philadelphia, PA: Saunders; 2012: 728-733.
63. Oyston PCF, Quarry JE. Tularemia vaccine: past, present, and future.Antoine van Leeuwenhoek. 2005;87(4):277-281.
65. Barquet N, Domingo P. Smallpox: the triumph over the most terrible of the ministers of death.Ann Intern Med. 1997;127(8):635-642.
66. Dowd GE.War Under Heaven: Pontiac, the Indian Nations, and the British Empire. Baltimore, MD: Johns Hopkins University Press; 2004.
67. Brennan JG, Henderson DA. Diagnosis and management of smallpox.N Engl J Med. 2002;346(17):1300-1308.
68. Centers for Disease Control and Prevention. Smallpox: Diagnosis and Evaluation. Available at https://www.cdc.gov/smallpox/hcp/diagnosis-testing/. Last accessed August 26, 2026.
69. Alibek K, Handelman S.Biohazard: The Chilling True Story of the Largest Covert Biological Weapons Program in the World. New York, NY: Random House; 1999.
70. Fenner F, Henderson DA, Arita A, Jezek Z, Ladnyl ID.Smallpox and its Eradication. Geneva: World Health Organization; 1988.
71. Centers for Disease Control and Prevention. Evaluating Patients for Smallpox: Acute, Generalized Vesicular or Pustular Rash Illness Protocol. Available at https://www.cdc.gov/smallpox/hcp/diagnosis-testing/evaluating-patients-rash-illness-protocol.html. Last accessed August 26, 2026.
72. Hussain AN. Smallpox. Available at https://emedicine.medscape.com/article/237229-overview. Last accessed August 26, 2026.
73. Centers for Disease Control and Prevention. Bioterrorism and Smallpox: The Threat. Available at https://www.cdc.gov/smallpox/bioterrorism/. Last accessed August 26, 2026.
74. Texas Department of Health. Emergency Preparedness and Response. Available at https://www.texascountyhealth.org/emergency-preparedness. Last accessed August 26, 2026.
75. Centers for Disease Control and Prevention. Laboratory Information for Smallpox. Available at https://www.cdc.gov/smallpox/hcp/laboratories/. Last accessed August 26, 2026.
76. World Health Organization. Smallpox. Available at https://www.who.int/health-topics/smallpox#tab=tab_1. Last accessed August 26, 2026.
77. Centers for Disease Control and Prevention. Smallpox Vaccine. Available at https://www.cdc.gov/smallpox/vaccines/. Last accessed August 26, 2026.
78. Lanier R, Trost L, Tippin T, et al. Development of CMX001 for the treatment of poxvirus infections.Viruses. 2010;2(12):2740-2762.
79. U.S. Food and Drug Administration. FDA Approves Drug to Treat Smallpox. Available at https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-drug-treat-smallpox. Last accessed August 26, 2026.
80. Grosenbach DW, Honeychurch K, Rose E, et al. Oral tecovirimat for the treatment of smallpox.N Engl J Med. 2018;379(1):44-53.
81. Centers for Disease Control and Prevention. Smallpox: Vaccine Adverse Events. Available at https://www.cdc.gov/smallpox/hcp/vaccines/vaccine-adverse-events.html. Last accessed August 26, 2026.
82. MedlinePlus. Cidofovir Injection. Available at https://medlineplus.gov/druginfo/meds/a696037.html. Last accessed August 26, 2026.
83. University of Maryland Medical Center. Important Information About Vaccinia (Smallpox) Vaccine. Available at https://health.umd.edu/sites/default/files/2024-07/Important%20Information%20About%20Vaccinia%20%28Smallpox%29%20Vaccine.pdf. Last accessed August 26, 2026.
84. Petersen BW, Harms TJ, Reynolds MG Harrison LH. Use of vaccinia virus smallpox vaccine in laboratory and health care personnel at risk for occupational exposure to orthopoxviruses – recommendations of the Advisory Committee on Immunization Practices (ACIP), 2015.MMWR. 2016;65(10):257-262.
85. Centers for Disease Control and Prevention. About Smallpox Vaccines. Available at https://www.cdc.gov/smallpox/hcp/vaccines/index.html. Last accessed August 26, 2026.
86. U.S. Food and Drug Administration. Smallpox. Available at https://www.fda.gov/vaccines-blood-biologics/vaccines/smallpox. Last accessed August 26, 2026.
87. Hatch GJ, Graham VA, Bewley KR, et al. Assessment of the protective effect of Imvamune and Acam2000 vaccines against aerosolized monkeypox virus in cynomolgus macaques.J Virol. 2013;87(14):7805-7815.
88. U.S. Food and Drug Administration. Package Insert: ACAM2000 (Smallpox Vaccine). Available at https://www.fda.gov/media/75792/download. Last accessed August 26, 2026.
89. Fierce Pharma. Bavarian Nordic Completes Delivery of 20 Million Doses of IMVAMUNE Smallpox Vaccine to the U.S. Strategic National Stockpile. Available at https://www.fiercepharma.com/search-results?fulltext_search=Bavarian+Nordic+Completes+Delivery+of+20+Million+Doses+of+IMVAMUNE+Smallpox+Vaccine+to+the+U.S.+Strategic+National+Stockpile&dns=fiercehealthcare_com%2Cfiercebiotech_com%2Cfiercepharma_com.accessed August 26, 2026.
90. Centers for Disease Control and Prevention. Smallpox-Monkeypox Vaccine VIS. Available at https://www.cdc.gov/vaccines/hcp/current-vis/smallpox-monkeypox.html. Last accessed August 26, 2026.
91. PR Newswire. FDA Approves First Live, Non-Replicating Vaccine to Prevent Smallpox and Monkeypox. Available at https://www.prnewswire.com/news-releases/fda-approves-first-live-non-replicating-vaccine-to-prevent-smallpox-and-monkeypox-300924574.html. Last accessed August 26, 2026.
92. Petersen BW, Damon IK, Pertowski CA, et al. Clinical guidance for smallpox vaccine use in a postevent vaccination program.MMWR. 2015;64(RR02):1-26.
93. Centers for Disease Control and Prevention. Smallpox: Public Health Response Activities: Ring Vaccination. Available at https://www.cdc.gov/smallpox/php/bioterrorism-response-planning/public-health-response-activities.html. Last accessed August 26, 2026.
94. Borio L, Inglesby TV, Peters CJ, et al. Hemorrhagic fever viruses as biological weapons: medical and public health management.JAMA. 2002;287(18):2391-2405.
95. U.S. Army Medical Research and Materiel Command. Treatment of Viral Hemorrhagic Fevers with Intravenous Ribavirin in Military Treatment Facilities. Available at https://clinicaltrials.gov/ct2/show/NCT00992693. Last accessed August 26, 2026.
96. World Health Organization. Ribavirin: General Description. Available at https://list.essentialmeds.org/medicines/473. Last accessed August 26, 2026.
97. Cheng HY, French CE, Salam AP, et al. Lack of evidence for ribavirin treatment of lassa fever in systematic review of published and unpublished studies.Emerg Infect Dis. 2022;28(8):1559-1568.
98. Centers for Disease Control and Prevention. About Viral Hemorrhagic Fevers. Available at https://www.cdc.gov/viral-hemorrhagic-fevers/about/index.html. Last accessed August 26, 2026.
99. Centers for Disease Control and Prevention. Viral Hemorrhagic Fevers. VHG Clinical Specimen Packaging and Shipping. Available at https://www.cdc.gov/viral-hemorrhagic-fevers/php/laboratories/specimen-packing.html. Last accessed August 26, 2026.
100. Racsa LD, Kraft CS, Olinger GG, Hensley LE. Viral hemorrhagic fever diagnostics.Clin Infect Dis. 2016;62(2):214-219.
101. Centers for Disease Control and Prevention. Interim Guidance for Managing Patients with Suspected Viral Hemorrhagic Fever in U.S. Hospitals. Available at https://stacks.cdc.gov/view/cdc/22139. Last accessed August 26, 2026.
102. U.S. Food and Drug Administration. For Physicians: How to Request Single Patient Expanded Access ("Compassionate Use"). Available at https://www.fda.gov/drugs/investigational-new-drug-ind-application/physicians-how-request-single-patient-expanded-access-compassionate-use. Last accessed August 26, 2026.
103. Centers for Disease Control and Prevention. Viral Hemorrhagic Fevers: Guidance for Personal Protective Equipment (PPE): Donning and Doffing PPE During Management of Patients with Selected VHF in U.S. Hospitals. Available at https://www.cdc.gov/viral-hemorrhagic-fevers/hcp/guidance/index.html. Last accessed August 26, 2026.
104. California Department of Industrial Relations, Division of Occupational Safety and Health. Interim Guidance on Ebola Virus. Available at https://www.dir.ca.gov/dosh/documents/Cal-OSHA-Guidance-on-Ebola-Virus.pdf. Last accessed August 26, 2026.
105. Public Health Agency of Canada.Clostridium botulinum: Infectious Substances Pathogen Safety Data Sheet. Available at https://www.canada.ca/en/public-health/services/laboratory-biosafety-biosecurity/pathogen-safety-data-sheets-risk-assessment/clostridium-botulinum.html. Last accessed August 26, 2026.
106. Frantz DR, Jahrling PB, Friedlander AM, et al. Clinical recognition and management of patients exposed to biological warfare agents.JAMA. 1997;278(5):399-411.
107. Shapiro RL, Hatheway C, Becher J, Swerdlow DL. Botulism surveillance and emergency response: a public health strategy for a global challenge.JAMA. 1997;278(5):433-435.
109. Villar RG, Elliott SP, Davenport KM. Botulism: the many faces of botulinum toxin and its potential for bioterrorism.Infect Dis Clin North Am. 2006;20(2):313-327.
110. Centers for Disease Control and Prevention. Botulism: Clinical Overview of Botulism. Available at https://www.cdc.gov/botulism/hcp/clinical-overview/. Last accessed August 26, 2026.
111. Rao AK, Sobel J, Chatham-Stephens K, Luquez C. Clinical guidelines for diagnosis and treatment of botulism, 2021.MMWR. 2021;70(2):1-30.
112. Centers for Disease Control and Prevention. Investigational heptavalent botulinum antitoxin (HBAT) to replace licensed botulinum antitoxin AB and investigational botulinum antitoxin E.MMWR. 2010;59(10):299.
113. U.S. Food and Drug Administration. FDA Approves First Botulinum Antitoxin for Use in Neutralizing All Seven Known Botulinum Nerve Toxin Serotypes. Available at https://wayback.archive-it.org/7993/20161022134538/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm345128.htm. Last accessed August 26, 2026.
114. Varma JK, Katsitadze G, Moiscrafishvili M, et al. Signs and symptoms predictive of death in patients with foodborne botulism—Republic of Georgia, 1980–2002.Clin Infect Dis. 2004;39(3):357-362.
115. Centers for Disease Control and Prevention. Investigation of a ricin-containing envelope at a postal facility—South Carolina, 2003.MMWR. 2003;52(46):1129-1131.
116. Shea D, Gottron F.CRS Report for Congress. Ricin: Technical Background and Possible Role in Terrorism. Washington, DC: Library of Congress; 2004.
117. Centers for Disease Control and Prevention. Health Advisory: CDC Alert on Ricin. Available at https://stacks.cdc.gov/view/cdc/25183. Last accessed August 26, 2026.
118. Centers for Disease Control and Prevention. Chemical Emergencies: Ricin. Available at https://www.cdc.gov/chemical-emergencies/chemical-fact-sheets/ricin.html. Last accessed August 26, 2026.
119. U.S. Department of Health and Human Services Office of Public Health Emergency Preparedness.Response to a Ricin Incident: Guidelines for Federal, State, and Local Public Health and Medical Officials. Washington, DC: Department of Health and Human Services; 2006.
120. U.S. Army Medical Research and Material Command. USAMRIID Begins Clinical Trial of New Vaccine to Protect Against Ricin Toxin. Available at https://usamriid.health.mil/assets/docs/news/2011/Ricin_News_Release_13_Apr_2011.pdf. Last accessed August 26, 2026.
121. O'Hara JM, Brey RN 3rd, Mantis NJ. Comparative efficacy of two leading candidate ricin toxin a subunit vaccines in mice.Clin Vaccine Immunol. 2013;20(6):789-794.
122. Soligenix. Soligenix Receives Additional NIAID Funding to Advance Development of Heat Stable Ricin Vaccine. Available at https://www.prnewswire.com/news-releases/soligenix-receives-additional-niaid-funding-to-advance-development-of-heat-stable-ricin-vaccine-300476933.html. Last accessed August 26, 2026.
123. Soligenix, Inc. Soligenix Announces Publication Demonstrating Positive Correlates of Protection with RiVax in Nonhuman Primate Survival after Ricin Challenge. Available at https://www.prnewswire.com/news-releases/soligenix-announces-publication-demonstrating-positive-correlates-of-protection-with-rivax-in-non-human-primate-survival-after-ricin-challenge-301706790.html. Last accessed August 26, 2026.
124. Brey RN III, Mantis NJ, Pincus SH, Vitetta ES, Smith LA, Roy CJ. Recent advances in the development of vaccines against. Ricin.Hum Vaccin Immunother. 2016;12(5):1196-1201.
125. Centers for Disease Control and Prevention. CDC Contact Information for Healthcare Professionals. Available at https://www.cdc.gov/yellow-book/hcp/about/cdc-contact-information-for-healthcare-professionals.html. Last accessed August 26, 2026.
126. CDC Stacks. Bioterrorism Readiness Plan: A Template for Healthcare Facilities. Available at https://stacks.cdc.gov/view/cdc/11287. Last accessed August 26, 2026.
- Back to Course Home
- Participation Instructions
- Review the course material online or in print.
- Complete the course evaluation.
- Review your Transcript to view and print your Certificate of Completion. Your date of completion will be the date (Pacific Time) the course was electronically submitted for credit, with no exceptions. Partial credit is not available.